The ME PMP email address is provided, along with website addresses for general information, enrollment, access to data, data upload, and statistics. Contact information is provided for the PMP Coordinator. Data for 2017 cover the state population (1,341,582), DEA registered prescribers (8,581), and DEA registered dispensers (323). ME PMP available reports are listed. For 2018, ME PMP funding sources were the state general fund and a CDC grant. For 2018, ME PMP personnel numbers are reported for the following job categories: operational (3), technical (3), analytical (2), and "other" (0). Significant ME PMP dates are reported for enabling legislation (June 2003), becoming operational (July 2004), initial user access (January 2005), on-line access (January 2005), and electronic reporting (July 2004). Access information is provided for statutes and rules relevant to ME PMP policies and procedures. Data are required to be reported by prescribers on the next business day after prescribing any of the following drugs: controlled substances in schedules II, III, and IV, and any other drugs specified by the ME PMP, including naloxone administering information and opioid-related drug overdoses or deaths. Registrant's disciplinary history and status are also required to be reported. Miscellaneous ME PMP capabilities and policies are listed. Both prescribers and dispensers are required to enroll with and use the ME PMP. A subpoena and written request are required for a law enforcement agency to access ME PMP patient drug-use data. The data retention policy includes the eventual purging of all information that is 6-years old. Training in ME PMP use is available, but not required. Other information addresses ME PMP technological capabilities and reports authorized for production by requestors.
Prescription Drug Monitoring Program: Maine State Profile
NCJ Number
253005
Date Published
August 2018
Length
8 pages
Annotation
Information and data are presented for the Maine Prescription Monitoring Program (ME PMP), which is administered by the Maine Department of Health and Human Services, Office of Substance Abuse.
Abstract